Chatting with ET after receiving the Lifetime Achievement Award for 2025 as a part of the ET Awards for Company Excellence, Poonawalla, nonetheless, harassed on the necessity for better investments in R&D, accelerated regulatory approvals and making provide chains stronger to assist retain India’s international management place in vaccines. Edited excerpts:
How does it really feel to obtain ET’s Lifetime Achievement Award?
It’s at all times humbling to be recognised, particularly by a platform like The Financial Occasions that has chronicled India’s development story so intently. I see this not as a private accolade, however as a recognition of the work completed by hundreds of individuals at Serum Institute over the previous a number of a long time. It’s a reminder that our efforts in making vaccines reasonably priced and accessible have had a significant influence, and that duty continues.
Because the founding father of SII, what does this award imply in your organisation?
It’s an affirmation of the trail we selected very early on…to give attention to scale, affordability, and high quality. We operated in an area that was as soon as dominated by multinational corporations, and we demonstrated that it’s attainable to ship world-class vaccines from India to the world. This recognition belongs equally to our scientists, our companions, and our collaborators globally who’ve trusted us over time.
Additionally Learn: Iran struggle influence: Important medication could price as much as 5% extra, for now
How do you describe your six-decade-long journey of constructing Serum Institute?
It has been a journey pushed extra by goal than design. After we began, the target was simple-to be certain that life-saving vaccines should not be out of attain for individuals due to price or provide constraints. Over time, we constructed capabilities, invested in know-how, and expanded globally, however the core rules remained unchanged. There have been challenges at each stage, however consistency of imaginative and prescient and long-term considering have helped us construct what Serum Institute is right now.
To the subsequent technology of vaccine scientists, what’s your recommendation?
I might say give attention to influence at scale. Scientific excellence is important, however equally vital is knowing the place the necessity is best. The way forward for vaccines will rely not simply on innovation, however on how successfully these improvements may be delivered to populations at scale. Stay affected person, be rigorous in your work, and at all times maintain the bigger public good in thoughts.
Additionally Learn: Drug regulator halves approval timelines, eases a number of guidelines
What are the important thing elements that may strengthen India’s vaccine capabilities?
India already has sturdy fundamentals, scientific expertise, manufacturing scale, and a rising ecosystem. We’d like deeper funding in R&D, stronger collaboration between academia, business, and authorities, and sooner regulatory pathways with out compromising on security. Constructing long-term funding mechanisms for innovation and strengthening provide chains can even be vital if India is to stay a worldwide chief in vaccines.
The place do you see SII within the subsequent 2-3 a long time?
I see Serum Institute persevering with to evolve as a worldwide vaccine innovator. The main target shall be on new platforms, rising ailments, and preparedness for future pandemics. Affordability will stay central to our mission. With the subsequent technology now main operations, I’m assured that the organisation will proceed to develop whereas staying true to its founding values.
What are the few issues that you simply suppose may have been completed higher at your organisation?
In hindsight, there are at all times areas the place one may have moved sooner, notably increasing international partnerships sooner. Nonetheless, we’ve got typically taken a cautious and sustainable strategy, which has helped us construct long-term credibility. If something, we’ll proceed to put better emphasis on accelerating innovation whereas sustaining the standard and reliability that we’re identified for.
